ERBB2 and gastric adenocarcinoma: Human epidermal growth factor receptor (HER2) overexpression, found in 7–34% of gastric adenocarcinoma patients, is currently a decisive element in disease treatment, as these tumors are good responders to the monoclonal antibody trastuzumab [61].